Pirarubicin combined with TLR3 or TLR4 agonists enhances anti-tumor efficiency
Article in International Immunopharmacology (December 2024)
The most recent citing publications are shown below. View all 22 publications that cite this research output on Dimensions.
Targeting Tumor-Associated Macrophages with the Immune-Activating Nanomedicine for Achieving Strong Antitumor Activity with Rapid Clearance from the Body
Article in ACS Nano (August 2024)
Participation of TLRs in cancer immunopathogenesis and drug resistance via interacting with immunological and/or non-immunological signaling pathways as well as lncRNAs
Article in International Immunopharmacology (July 2024)